Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Targeting iron metabolism in drug discovery and delivery.

Crielaard BJ, Lammers T, Rivella S.

Nat Rev Drug Discov. 2017 Jun;16(6):400-423. doi: 10.1038/nrd.2016.248. Epub 2017 Feb 3. Review.

2.

Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.

Li H, Choesang T, Bao W, Chen H, Feola M, Garcia-Santos D, Li J, Sun S, Follenzi A, Pham P, Liu J, Zhang J, Ponka P, An X, Mohandas N, Fleming RE, Rivella S, Li G, Ginzburg YZ.

Blood. 2017 Mar 16;129(11):1514-1526. doi: 10.1182/blood-2016-09-742387. Epub 2017 Feb 1.

PMID:
28151426
3.

Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Günther disease model.

Millot S, Delaby C, Moulouel B, Lefebvre T, Pilard N, Ducrot N, Ged C, Lettéron P, de Franceschi L, Deybach JC, Beaumont C, Gouya L, De Verneuil H, Lyoumi S, Puy H, Karim Z.

Haematologica. 2017 Feb;102(2):260-270. doi: 10.3324/haematol.2016.151621. Epub 2016 Nov 10.

4.

Hematological disorders and pulmonary hypertension.

Mathew R, Huang J, Wu JM, Fallon JT, Gewitz MH.

World J Cardiol. 2016 Dec 26;8(12):703-718. doi: 10.4330/wjc.v8.i12.703. Review.

5.

New strategies to target iron metabolism for the treatment of beta thalassemia.

Oikonomidou PR, Casu C, Rivella S.

Ann N Y Acad Sci. 2016 Mar;1368(1):162-8. doi: 10.1111/nyas.13018. Epub 2016 Feb 25.

6.

Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation.

Chen H, Choesang T, Li H, Sun S, Pham P, Bao W, Feola M, Westerman M, Li G, Follenzi A, Blanc L, Rivella S, Fleming RE, Ginzburg YZ.

Haematologica. 2016 Mar;101(3):297-308. doi: 10.3324/haematol.2015.127902. Epub 2015 Dec 3.

7.

Oxidative stress in β-thalassaemia and sickle cell disease.

Voskou S, Aslan M, Fanis P, Phylactides M, Kleanthous M.

Redox Biol. 2015 Dec;6:226-39. doi: 10.1016/j.redox.2015.07.018. Epub 2015 Aug 1. Review.

8.

Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, Nemeth E, Ganz T.

Blood. 2015 Oct 22;126(17):2031-7. doi: 10.1182/blood-2015-07-658419. Epub 2015 Aug 14.

9.

Genomic approaches to identifying targets for treating β hemoglobinopathies.

Ngo DA, Steinberg MH.

BMC Med Genomics. 2015 Jul 29;8:44. doi: 10.1186/s12920-015-0120-2. Review.

10.

Neonatal CD71+ Erythroid Cells Do Not Modify Murine Sepsis Mortality.

Wynn JL, Scumpia PO, Stocks BT, Romano-Keeler J, Alrifai MW, Liu JH, Kim AS, Alford CE, Matta P, Weitkamp JH, Moore DJ.

J Immunol. 2015 Aug 1;195(3):1064-70. doi: 10.4049/jimmunol.1500771. Epub 2015 Jun 22.

11.

Increasing serum transferrin to reduce tissue iron overload due to ineffective erythropoiesis.

Tolosano E.

Haematologica. 2015 May;100(5):565-6. doi: 10.3324/haematol.2015.124966. No abstract available.

12.

β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Rivella S.

Haematologica. 2015 Apr;100(4):418-30. doi: 10.3324/haematol.2014.114827. Review.

13.

Anemia: progress in molecular mechanisms and therapies.

Sankaran VG, Weiss MJ.

Nat Med. 2015 Mar;21(3):221-30. doi: 10.1038/nm.3814. Review.

14.

New insights into iron regulation and erythropoiesis.

Kim A, Nemeth E.

Curr Opin Hematol. 2015 May;22(3):199-205. doi: 10.1097/MOH.0000000000000132. Review.

15.

Iron age: novel targets for iron overload.

Casu C, Rivella S.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):216-21. doi: 10.1182/asheducation-2014.1.216. Epub 2014 Nov 18. Review.

16.

Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice.

Gelderman MP, Baek JH, Yalamanoglu A, Puglia M, Vallelian F, Burla B, Vostal J, Schaer DJ, Buehler PW.

Haematologica. 2015 May;100(5):611-22. doi: 10.3324/haematol.2014.117325. Epub 2015 Jan 23.

17.

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.

Schmidt PJ, Racie T, Westerman M, Fitzgerald K, Butler JS, Fleming MD.

Am J Hematol. 2015 Apr;90(4):310-3. doi: 10.1002/ajh.23934.

18.

Low intracellular iron increases the stability of matriptase-2.

Zhao N, Nizzi CP, Anderson SA, Wang J, Ueno A, Tsukamoto H, Eisenstein RS, Enns CA, Zhang AS.

J Biol Chem. 2015 Feb 13;290(7):4432-46. doi: 10.1074/jbc.M114.611913. Epub 2014 Dec 30.

19.

Myelodysplasia is in the niche: novel concepts and emerging therapies.

Bulycheva E, Rauner M, Medyouf H, Theurl I, Bornhäuser M, Hofbauer LC, Platzbecker U.

Leukemia. 2015 Feb;29(2):259-68. doi: 10.1038/leu.2014.325. Epub 2014 Nov 14. Review.

20.

Altered erythropoiesis and iron metabolism in carriers of thalassemia.

Guimarães JS, Cominal JG, Silva-Pinto AC, Olbina G, Ginzburg YZ, Nandi V, Westerman M, Rivella S, de Souza AM.

Eur J Haematol. 2015 Jun;94(6):511-8. doi: 10.1111/ejh.12464. Epub 2014 Nov 11.

Supplemental Content

Support Center